WA's medicinal cannabis industry has notched another win for the week, with Zelira Therapeutics attaining $33 million in non-dilutive funding for its cannabis-based autism treatment.
Argent Biopharma has streamlined its asset acquisition of fellow WA cannabis player AusCann, while another Perth player has been subject to a reverse takeover.
Medical cannabis company Little Green Pharma's founder Fleta Solomon has stepped down as chief executive to reduce her workload and focus on other divisions of the business.
A subsidiary of medicinal cannabis company Little Green Pharma has partnered with Health Insurance Fund of Australia to develop a Perth-based mental health treatment facility.
Little Green Pharma has revealed plans to demerge its psychedelics business into a separate unlisted entity, while forming a research partnership with Curtin University.
New data details the expansion of Andrew and Nicola Forrest's private company, Tattarang. Click through to see our latest ranking and analysis of Western Australia's largest private companies.
Hancock Prospecting will own a 10 per cent stake in Western Australian medicinal cannabis company Little Green Pharma after participating in a $27.2 million capital raising.
HIF has declared its support for medicinal cannabis, offering rebates for treatments and partnering with Little Green Pharma to collaborate on research.
Our weekly appointments wrap includes Andrew Stevens, David Crothers, Bellevue Gold, Paul Good, Ken Seymour, John O'Neil, Wally Newman, Neil Foster, Dominic Da Cruz, Jason Kunkler and Stacey Molloy.
Little Green Pharma began trading on the ASX today, with its shares closing 10 cents below the price of its initial public offering, despite signing a five-year supply contract with a UK pharmaceutical company overnight.
Emerald Clinics and Little Green Pharma have both completed their initial public offerings ahead of stock market listings this month, with Emerald getting ready for its ASX debut tomorrow.
Perth companies Emerald Clinics and Little Green Pharma are seeking to raise up to $18 million ahead of stock market listings as they pursue very different strategies in the medicinal cannabis market.
